|
Press Releases |
|
 |
|
Friday, March 21, 2025 |
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum |
On March 17, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. more info >> |
|
Friday, February 14, 2025 |
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
Friday, January 24, 2025 |
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
Thursday, January 9, 2025 |
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
Monday, December 9, 2024 |
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
Monday, December 2, 2024 |
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
Monday, October 21, 2024 |
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
Tuesday, September 24, 2024 |
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
Friday, August 16, 2024 |
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
Monday, August 5, 2024 |
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Ensign InfoSecurity Recognised in MITRE's 2024 Impact Report for Contribution to Global Cyber Defence Research
May 9, 2025 11:00 HKT/SGT
|
|
|
Unlocking the Full Potential of GCCs: The Strategic Power of Cultural Integration
May 9, 2025 02:53 HKT/SGT
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 9, 2025 02:14 HKT/SGT
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 9, 2025 01:45 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 9, 2025 01:00 HKT/SGT
|
|
|
Thailand, Led by DPM Prasert, to Showcase Leadership in Hosting the 3rd UNESCO Global Forum on the Ethics of AI 2025
May 9, 2025 00:10 HKT/SGT
|
|
|
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft
May 9, 2025 00:00 HKT/SGT
|
|
|
The 33rd China Cycle 2025 Grandly Commences
May 8, 2025 17:00 HKT/SGT
|
|
|
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations
May 8, 2025 16:54 HKT/SGT
|
|
|
Malaysia Cybersecurity Center of Excellence Marks First Anniversary with New Partnerships, Scholarships and Expanded Programs
May 8, 2025 12:00 HKT/SGT
|
|
|
Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026
May 8, 2025 11:25 JST
|
|
|
Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV
May 8, 2025 11:08 JST
|
|
|
New Godzilla the Ride Film to Be Directed by Academy Award-Winning Takashi Yamazaki
May 8, 2025 10:00 HKT/SGT
|
|
|
Sensiba Welcomes Six New Partners in Firm's Largest Single-Year Expansion
May 8, 2025 01:00 HKT/SGT
|
|
|
CALB (3931.HK) Announces Proposed Controlling Shareholding in Jiangsu Olive Sensors
May 7, 2025 21:08 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|